Related content

The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS

By Guerard Pascal   Rakotoniaina Zo   Goirand Françoise   Rochette Luc   Dumas Monique   Lirussi Frederic   Bardou Marc  

Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 373, Iss. 6, 2006-09 ,pp. : 401-414

Springer Publishing Company

Access to resources Recommend Favorite

HMG-CoA reductase inhibitors: First report of decreased libido with atorvastatin, fluvastatin, pravastatin and simvastatin: 8 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1039, 2005-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Celecoxib but not the combination of celecoxib+atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat

By Rakotoniaina Zo  

Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 378, Iss. 3, 2008-09 ,pp. : 241-251

Springer Publishing Company

Access to resources Recommend Favorite

The effect of HMG-CoA reductase inhibitors on chronic allograft rejection

By Jones T.  

Expert Opinion on Emerging Drugs, Vol. 6, Iss. 1, 2001-04 ,pp. : 95-109

Informa Healthcare

Access to resources Recommend Favorite

Synthesis and Biological Evaluation of Atorvastatin Derivatives as Novel HMG-CoA Reductase Inhibitors

By  

Letters in Drug Design & Discovery, Vol. 10, Iss. 9, 2013-01 ,pp. : 817-822

Bentham Science Publishers

Access to resources Recommend Favorite